Although the selectivity data over SIRT2 are contrasting (2–159‐fold, depending on the study),293, 294, 296, 2979a still represents one of the most promising SIRT1i and, given its good drug‐like properties it was brought to clinical trials where it was shown to be safe308 and effective in early HD patients.309. This evidence concerns the gene SIRT2 and Huntington disease.